Nurix Therapeutics
(NASDAQ) NRIX
Nurix Therapeutics Financials at a Glance
Market Cap
$1.55B
Revenue (TTM)
$83.98M
Net Income (TTM)
$264.46M
EPS (TTM)
$-3.04
P/E Ratio
-4.95
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Price
$14.96
Volume
46,987
Open
$14.96
Price
$14.96
Volume
46,987
Open
$14.96
Previous Close
$14.96
Daily Range
$14.61 - $15.40
52-Week Range
$8.18 - $22.50
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Price
$14.96
Volume
46,987
Open
$14.96
Previous Close
$14.96
Daily Range
$14.61 - $15.40
52-Week Range
$8.18 - $22.50
NRIX News
NRIX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Nurix Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
317
CEO
Arthur T. Sands, MD, PhD
Website
www.nurixtx.comHeadquarters
San Francisco, CA 94158, US
NRIX Financials
Key Financial Metrics (TTM)
Gross Margin
-87%
Operating Margin
-3%
Net Income Margin
-3%
Return on Equity
-50%
Return on Capital
-47%
Return on Assets
-38%
Earnings Yield
-20.20%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.55B
Shares Outstanding
102.84M
Volume
46.99K
Short Interest
0.00%
Avg. Volume
1.11M
Financials (TTM)
Gross Profit
$65.12M
Operating Income
$285.67M
EBITDA
$244.84M
Operating Cash Flow
$249.47M
Capital Expenditure
$14.00M
Free Cash Flow
$263.47M
Cash & ST Invst.
$592.94M
Total Debt
$55.73M
Nurix Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$13.58M
+2.2%
Gross Profit
$8.95M
+116.6%
Gross Margin
65.89%
N/A
Market Cap
$1.55B
N/A
Market Cap/Employee
$5.41M
N/A
Employees
286
N/A
Net Income
$78.22M
-33.6%
EBITDA
$68.96M
-8.8%
Quarterly Fundamentals
Net Cash
$537.21M
-7.6%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$52.91M
+160.8%
Short Term Debt
$2.82M
-64.8%
Return on Assets
-38.43%
N/A
Return on Invested Capital
-47.48%
N/A
Free Cash Flow
$72.96M
-43.5%
Operating Cash Flow
$67.83M
-39.1%